The Effect of Different Macronutrients on Ileal Brake Activation
Primary Purpose
Obesity, Overweight
Status
Completed
Phase
Not Applicable
Locations
Netherlands
Study Type
Interventional
Intervention
Casein
Casein
Sucrose
Sucrose
Saline
Safflower oil
Sponsored by

About this trial
This is an interventional prevention trial for Obesity focused on measuring Ileal brake, Casein, Sucrose, Ileal infusion
Eligibility Criteria
Inclusion Criteria:
- Based on medical history and previous examination, no gastrointestinal complaints can be defined.
- Age between 18 and 55 years. This study will include healthy adult subjects (Male and Female), Women must be taking oral contraceptives. Subjects over 55 years have an increased risk for comorbidities, therefore, subjects over 55 years will not be included.
- BMI between 18 and 29 kg/m2
- Less then 2 'yes' responses in the SCOFF questionnaire (see appendix F1)
- Weight stable over at least the last 6 months
Exclusion Criteria:
- History of severe cardiovascular, respiratory, urogenital, gastrointestinal/ hepatic, hematological/immunologic, HEENT (head, ears, eyes, nose, throat), dermatological/connective tissue, musculoskeletal, metabolic/nutritional, endocrine, neurological/psychiatric diseases, allergy, major surgery and/or laboratory assessments which might limit participation in or completion of the study protocol. The severity of the disease (major interference with the execution of the experiment or potential influence on the study outcomes) will be decided by the principal investigator.
- Use of medication, including vitamin supplementation, except oral contraceptives, within 14 days prior to testing
- Administration of investigational drugs or participation in any scientific intervention study which may interfere with this study (to be decided by the principle investigator), in the 180 days prior to the study
- Major abdominal surgery interfering with gastrointestinal function (uncomplicated appendectomy, cholecystectomy and hysterectomy allowed, and other surgery upon judgement of the principle investigator)
- Dieting (medically prescribed, vegetarian, diabetic, macrobiological, biological dynamic)
- Pregnancy, lactation
- Excessive alcohol consumption (>20 alcoholic consumptions per week)
- Smoking
- Blood donation within 3 months before the study period
- Self-admitted HIV-positive state
- Eating disorders detected using the 'SCOFF questionnaire' (in Dutch translation)
- Lactose or cow milk intolerance
Sites / Locations
- Maastricht University Medical Center
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Arm 6
Arm Type
Experimental
Experimental
Experimental
Experimental
Placebo Comparator
Active Comparator
Arm Label
Low dose casein
High dose casein
Low dose sucrose
High dose sucrose
Placebo
Safflower oil
Arm Description
Ileal infusion of low dose casein
Ileal infusion of high dose casein
Ileal infusion of low dose sucrose
Ileal infusion of high dose sucrose
Ileal infusion saline
Ileal infusion safflower oil
Outcomes
Primary Outcome Measures
Difference in satiation (as measured by VAS) and food intake as measured during an ad libitum meal
Secondary Outcome Measures
Measurements in plasma and/or platelet poor plasma Plasma levels of the gut hormone Cholecystokinin (CCK)
Gastric emptying by using the C13 stable isotope breath test
Small bowel transit time by using lactulose hydrogen breath test
Gallbladder volumes by gallbladder ultrasound
Measurements in plasma and/or platelet poor plasma Plasma levels of the gut hormone Glucagon Like Peptide-1 (GLP-1)
Measurements in plasma and/or platelet poor plasma Plasma levels of the gut hormone peptide YY (PYY)
Full Information
NCT ID
NCT01509469
First Posted
August 9, 2011
Last Updated
January 28, 2014
Sponsor
Maastricht University Medical Center
Collaborators
Top Institute Food and Nutrition
1. Study Identification
Unique Protocol Identification Number
NCT01509469
Brief Title
The Effect of Different Macronutrients on Ileal Brake Activation
Official Title
The Effect of Different Macronutrients on Ileal Brake Activation
Study Type
Interventional
2. Study Status
Record Verification Date
January 2014
Overall Recruitment Status
Completed
Study Start Date
March 2012 (undefined)
Primary Completion Date
June 2013 (Actual)
Study Completion Date
June 2013 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Maastricht University Medical Center
Collaborators
Top Institute Food and Nutrition
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to determine whether ileal infusion of casein and sucrose can activate the ileal brake.
Detailed Description
The appearance of a food matrix into the duodenum, both during a meal and during the postprandial phase results in a feed-back from different parts of the intestine to the stomach, to the small intestine and to the central nervous system. All these processes inhibit, in concert, food processing in the gastrointestinal tract, satiation and appetite sensations and, consequently, food intake. These processes are involved in the so-called intestinal brake. The location at which the feedback process is initiated determines the severity of the brake effect; the entry of nutrients into the duodenum and jejunum activates the so-called duodenal and jejunal "brakes": negative feedback mechanisms that influence the function of more proximal parts of the gastrointestinal tract. Activation of both of these feedback mechanisms results in reduction of food intake and inhibition of hunger, probably partly by inhibition of gastric emptying rate (thus contributing to enhanced and prolonged gastric distension) and small intestinal transit time. More distal in the small intestine, the ileal brake is a feedback mechanism that results in inhibition of proximal gastrointestinal motility and secretion and increase feelings of satiation and reduction of ad libitum food intake.These results all point to a potentially powerful role of the ileal brake in the regulation of digestion, with direct or indirect impact upon eating behaviour and satiation.
The current scientific data strongly suggest that activation of the ileal brake provides the most powerful feedback mechanism to gastrointestinal transit and, especially, satiety signals and food intake. Most studies have used fat as macronutrient. The effects of several amounts, types and preparations of fat on the ileal brake have previously been investigated and reported.
Until present, the effects of the other macronutrients to induce the ileal brake remain largely unknown. There is evidence that carbohydrates induce the ileal brake. Proteins may also exert effects, although data are scarce and not convincing. However, it becomes more and more accepted that proteins may induce stronger effects on satiation and food intake than fat or carbohydrates.
In this study we're going to investigate the effect of intraileal infusion of casein and sucrose on ileal brake activation.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obesity, Overweight
Keywords
Ileal brake, Casein, Sucrose, Ileal infusion
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
15 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Low dose casein
Arm Type
Experimental
Arm Description
Ileal infusion of low dose casein
Arm Title
High dose casein
Arm Type
Experimental
Arm Description
Ileal infusion of high dose casein
Arm Title
Low dose sucrose
Arm Type
Experimental
Arm Description
Ileal infusion of low dose sucrose
Arm Title
High dose sucrose
Arm Type
Experimental
Arm Description
Ileal infusion of high dose sucrose
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Ileal infusion saline
Arm Title
Safflower oil
Arm Type
Active Comparator
Arm Description
Ileal infusion safflower oil
Intervention Type
Dietary Supplement
Intervention Name(s)
Casein
Intervention Description
Ileal infusion of low dose casein (5 gram)
Intervention Type
Dietary Supplement
Intervention Name(s)
Casein
Intervention Description
Ileal infusion of high dose casein (15 gram)
Intervention Type
Dietary Supplement
Intervention Name(s)
Sucrose
Intervention Description
Ileal infusion of low dose sucrose (4.3 gram)
Intervention Type
Dietary Supplement
Intervention Name(s)
Sucrose
Intervention Description
Ileal infusion of high dose sucrose (12.9 gram)
Intervention Type
Other
Intervention Name(s)
Saline
Intervention Description
Ileal infusion with saline (180mL in total)
Intervention Type
Dietary Supplement
Intervention Name(s)
Safflower oil
Intervention Description
Ileal infusion with safflower oil (6gr safflower oil in water)
Primary Outcome Measure Information:
Title
Difference in satiation (as measured by VAS) and food intake as measured during an ad libitum meal
Time Frame
1 day
Secondary Outcome Measure Information:
Title
Measurements in plasma and/or platelet poor plasma Plasma levels of the gut hormone Cholecystokinin (CCK)
Time Frame
1 day
Title
Gastric emptying by using the C13 stable isotope breath test
Time Frame
1 day
Title
Small bowel transit time by using lactulose hydrogen breath test
Time Frame
1 day
Title
Gallbladder volumes by gallbladder ultrasound
Time Frame
1 day
Title
Measurements in plasma and/or platelet poor plasma Plasma levels of the gut hormone Glucagon Like Peptide-1 (GLP-1)
Time Frame
1 day
Title
Measurements in plasma and/or platelet poor plasma Plasma levels of the gut hormone peptide YY (PYY)
Time Frame
1 day
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Based on medical history and previous examination, no gastrointestinal complaints can be defined.
Age between 18 and 55 years. This study will include healthy adult subjects (Male and Female), Women must be taking oral contraceptives. Subjects over 55 years have an increased risk for comorbidities, therefore, subjects over 55 years will not be included.
BMI between 18 and 29 kg/m2
Less then 2 'yes' responses in the SCOFF questionnaire (see appendix F1)
Weight stable over at least the last 6 months
Exclusion Criteria:
History of severe cardiovascular, respiratory, urogenital, gastrointestinal/ hepatic, hematological/immunologic, HEENT (head, ears, eyes, nose, throat), dermatological/connective tissue, musculoskeletal, metabolic/nutritional, endocrine, neurological/psychiatric diseases, allergy, major surgery and/or laboratory assessments which might limit participation in or completion of the study protocol. The severity of the disease (major interference with the execution of the experiment or potential influence on the study outcomes) will be decided by the principal investigator.
Use of medication, including vitamin supplementation, except oral contraceptives, within 14 days prior to testing
Administration of investigational drugs or participation in any scientific intervention study which may interfere with this study (to be decided by the principle investigator), in the 180 days prior to the study
Major abdominal surgery interfering with gastrointestinal function (uncomplicated appendectomy, cholecystectomy and hysterectomy allowed, and other surgery upon judgement of the principle investigator)
Dieting (medically prescribed, vegetarian, diabetic, macrobiological, biological dynamic)
Pregnancy, lactation
Excessive alcohol consumption (>20 alcoholic consumptions per week)
Smoking
Blood donation within 3 months before the study period
Self-admitted HIV-positive state
Eating disorders detected using the 'SCOFF questionnaire' (in Dutch translation)
Lactose or cow milk intolerance
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
A. Masclee, Prof.
Organizational Affiliation
Maastricht University Medical Centre +
Official's Role
Principal Investigator
Facility Information:
Facility Name
Maastricht University Medical Center
City
Maastricht
State/Province
Limburg
Country
Netherlands
12. IPD Sharing Statement
Citations:
PubMed Identifier
26872548
Citation
Ripken D, van Avesaat M, Troost FJ, Masclee AA, Witkamp RF, Hendriks HF. Intraileal casein infusion increases plasma concentrations of amino acids in humans: A randomized cross over trial. Clin Nutr. 2017 Feb;36(1):143-149. doi: 10.1016/j.clnu.2016.01.012. Epub 2016 Jan 29.
Results Reference
derived
Learn more about this trial
The Effect of Different Macronutrients on Ileal Brake Activation
We'll reach out to this number within 24 hrs